Open in interactive viewer → charts, metric popovers & call review

FitLife's First Debt Increase in Years Is a Bet on Peruvian Anchovies

A stock down 39% in ninety days met a quarter that wasn't bad — and management broke its deleveraging streak to lock in whey and fish oil before someone else does.
FTLF · Earnings Call · 2026-11-16

A price that has stopped believing the P&L

FitLife Brands walked into its 16 November call with the tape already having voted — and voted hard. The shares are down 38.5% over the last ninety trading days, from a 13 August peak of $11.19, and sit 67% below the October 2025 high of $20.76. That is a name in a drawdown, not a name in motion. And yet the quarter itself was not a disaster. Revenue of $25.6 million rose 9% year over year; net income of $1.6 million rose 71%; diluted EPS doubled to $0.16 from $0.09. The catch is in the same sentence: adjusted EBITDA fell to $3.3 million from $3.8 million, and revenue growth was largely the arithmetic of owning Irwin for a full quarter rather than the partial one a year ago. The reported gross margin of 37.7% looks like an improvement over 37.2%, until you remember last year's quarter carried $0.4 million of inventory step-up amortization — strip it out and the underlying margin fell about 1.2 points. Sequentially, at least, it improved from 37.0%. That is the honest shape of this business right now: four straight quarters of revenue between $25.3 million and $26.5 million, and adjusted EBITDA between $3.3 million and $3.7 million. A plateau, not a collapse. The market is pricing something else.

Two holes, and one balance sheet

Dayton Judd is unusually blunt about where the holes are. There are exactly two, and they are the same two he has been describing for over a year: MRC brands on Amazon, and specialty retail — GNC plus the independent health food channel. On the first, the question of whether the decline is moderating drew the most revealing answer of the call: “Yes, kind of, but not really.” — Dayton Judd, Host/Management · 2026-11-16 He then quantified it, which is better than the adjectives: MRC online revenue went roughly $5.1 million in Q1, $4.9 million in Q2, $4.5 million in Q3. Some of that is Prime Day migrating from Q3 into Q2, but the trend is still down. Compare that to August, when Judd told the same audience he “certainly [saw] some positive indications” — Dayton Judd, CEO · 2026-08-13 and wouldn't rule out an inflection. Three months later the inflection has not arrived — that walk-back is the story, not the headline numbers. On GNC, he was equally specific: roughly $10 million of trailing revenue, a ~10% customer, declining "maybe 15% to 25%" depending on quarter, driven by a double-digit fall in franchise doors plus negative same-store sales. It has been a topic on every call for years; on the August call he called it “lower than our expectations” — Dayton Judd, CEO · 2026-08-13. Nothing has changed except the degree of resignation.

Fish oil is the new whey

Here is what genuinely is new this quarter, and it is why the balance sheet moved. Net debt rose from $37.0 million to $38.6 million as working capital jumped from $9.6 million to $13.1 million — the first break in what management had repeatedly described as a general trend of reducing indebtedness each quarter.

whey, which has been our primary protein that we have used has gone from about $2.50 a pound a couple of years ago to it peaked around $15 a pound. It's now back down to between $9 and $10. So what we did is we started forward buying the whey last year. We bought a bunch at about $5 a pound, and we bought a bunch at $7.17 a pound.

Dayton Judd, Host/Management · 2026-11-16
That decision has now been vindicated in a way few hedges are. A year ago on the November 2025 call, Judd was already warning that purchases were being locked “at prices going up to $6.30 a pound” — Dayton Judd, CEO · 2025-11-13 with forward pricing "starting with the $7 now." Today he can say with a straight face that the forward book is why MusclePharm is taking share — competitors passed protein inflation through, FitLife largely did not, and MusclePharm gross margin has climbed from "around 20-ish percent" to north of 25% while online hit an all-time high. So they did it again, in a new commodity. Fish oil is the number-one keyword on this call for a reason: Peru cancelled a fishing season, the global catch is short, and FitLife has now locked cost for what it believes is most of its needs through Q4 2027 on roughly $600,000–$800,000 of payments. If the spot market stays ugly, that forward book converts into margin and share the same way the whey did. If it collapses, they have tied up cash at the top. Either way, the cash has already left, and that is why the debt line went the wrong way. It is also a full reversal of the April posture. After two and a half years of fighting protein costs, Judd told investors he would “never buy another brand that is IP only, and I will never buy another brand that is protein-dominant” — Dayton Judd, CEO · 2026-04-02. Six months later, the protein-heavy brand is the one printing all-time online highs — the lesson being less about acquisition discipline than about whose cost curve you happen to own.

What is actually getting better

The offsetting half of the story is real, if less dramatic. Irwin's online revenue reached $3.6 million, now 28% of Irwin's revenue versus roughly 5% a year ago, with an Amazon run rate above $12 million. Active Amazon subscribers rose to about 96,500 from 94,000 at the August call. The glass bottles problem — a genuine one, since every Irwin bottle shipped to Amazon must be unboxed, bubble-wrapped, stickered and reboxed at a cost that Judd pegs at more than $1 a unit — finally has a solution: dual pack-outs, glass for brick-and-mortar and plastic for Amazon on high-volume SKUs by late this year or early next, plus 2-pack listings that arbitrage Amazon's fulfillment tiers. That is a real gross-margin lever, not a talking point. And the cost actions are quantifiable: $1.2 million of annualized personnel savings flowing entirely through G&A beginning in Q4, plus a roughly halved Los Angeles lease and other procurement work. Against a company that just did $103.4 million of trailing revenue and $13.7 million of adjusted EBITDA, $1.2 million is not nothing.

The uncomfortable admission

The most quotable line on the call was not about Amazon algorithm changes, which are a genuinely recurring complaint, or the far-from-new admission that Irwin's online growth is cannibalizing wholesale — Judd concedes “I don't think we can argue at all that they're not” — Dayton Judd, Host/Management · 2026-11-16. It was this:

I think the way I would say it is everything is doing worse than it was a year ago, is probably the way I would say it.

Dayton Judd, Host/Management · 2026-11-16
That is a CEO refusing to spin, and it dovetails with what the wider market tape has been saying for months: challenging consumer environment and decline in wholesale both show up as gainers in the 90-day cross-market screen, led by apparel and packaged-goods names under the same pressure. FitLife is not idiosyncratically broken — it is small, levered and concentrated in exactly the channels consumers are abandoning. Which is what the multiple now says. At roughly 1.0x trailing revenue and 10.3x free cash flow, the stock has retraced to levels last seen before the Irwin acquisition re-rated it. Liabilities at 53.8% of assets is not distressed, but it is not the fortress Judd was building either. The bull case rests on one simple arithmetic fact: strip out MRC and the specialty retail channel — the two known, quantified bleeders — and the rest of the business is flat-to-growing, and the whole enterprise has been stable for four quarters while management quietly fixed the packaging, the shelf life, the cost base and two commodity exposures. The bear case is that Q4 is seasonally the weakest quarter in supplements, no guidance is being offered, and the balance sheet has stopped being a tailwind. Both are true. That is what a $64 million market cap looks like in a market that has decided to wait.